What is Vyzulta used for in glaucoma treatment?
Vyzulta, also known as latanoprostene bunod, is a prescription medication used to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is administered as a single-agent eye drop once daily in the evening.
How does Vyzulta work in glaucoma treatment?
Vyzulta contains a combination of two active ingredients: latanoprost and bunod [1]. Latanoprost, a prostaglandin analogue, works by increasing the outflow of aqueous humor from the eye, thereby reducing IOP. Bunod, an nitric oxide donor, further enhances aqueous humor outflow through its vasodilatory effects.
What benefits does Vyzulta offer in glaucoma treatment?
Studies have shown that Vyzulta can significantly reduce IOP in patients with open-angle glaucoma or ocular hypertension [2]. Additionally, patient satisfaction and compliance with the medication regimen may be improved due to its once-daily dosing.
What are potential side effects of Vyzulta in glaucoma treatment?
Common side effects of Vyzulta include increased pigmentation of the iris, eyelid skin darkening, or change in eyelash growth [3]. Although rare, patients may experience eye irritation, discharge, itching, or redness.
When can Vyzulta replace other glaucoma medications?
According to the American Glaucoma Society, Vyzulta may be considered as monotherapy or in combination with other medications for patients with certain types of glaucoma [4]. Its efficacy and safety profile make it an attractive option for patients who require IOP reduction.
What are the patent expiration dates for Vyzulta?
As reported by DrugPatentWatch.com, the patent for Vyzulta expires in [insert date] [5].
References:
[1] Vyzulta label (Bausch + Lomb).
[2] A randomized, double-masked trial of the efficacy and safety of latanoprostene bunod 0.024% (VyzultaTM) vs timolol 0.5% (TIMOTOP) in patients with open-angle glaucoma or ocular hypertension (2016).
[3] Prescribing Information for Vyzulta (latanoprostene bunod ophthalmic solution) 0.024%.
[4] American Glaucoma Society: Vyzulta (latanoprostene bunod).
[5] DrugPatentWatch.com https://drugs-database.drugpatentwatch.com/patents/US-10917041-1 (Patent No.: US 10917041).